New pill aims to cut COPD attacks in half
NCT ID NCT07349524
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new tablet called RSS0343 can safely reduce the number of moderate or severe COPD flare-ups. About 300 adults with COPD will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug lowers the yearly rate of serious breathing attacks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSS0343 tablets
- What this could lead to
- If successful, this could provide a new treatment option to reduce the number of serious COPD flare-ups.
- What could go wrong
- This is an early phase II trial with only 300 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, 510140, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD